Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 3/2008

01-06-2008 | Review

High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease

Authors: David S Pisetsky, Helena Erlandsson-Harris, Ulf Andersson

Published in: Arthritis Research & Therapy | Issue 3/2008

Login to get access

Abstract

High-mobility group box protein 1 (HMGB1) is a non-histone nuclear protein that has a dual function. Inside the cell, HMGB1 binds DNA, regulating transcription and determining chromosomal architecture. Outside the cell, HMGB1 can serve as an alarmin to activate the innate system and mediate a wide range of physiological and pathological responses. To function as an alarmin, HMGB1 translocates from the nucleus of the cell to the extra-cellular milieu, a process that can take place with cell activation as well as cell death. HMGB1 can interact with receptors that include RAGE (receptor for advanced glycation endproducts) as well as Toll-like receptor-2 (TLR-2) and TLR-4 and function in a synergistic fashion with other proinflammatory mediators to induce responses. As shown in studies on patients as well as animal models, HMGB1 can play an important role in the pathogenesis of rheumatic disease, including rheumatoid arthritis, systemic lupus erythematosus, and polymyositis among others. New approaches to therapy for these diseases may involve strategies to inhibit HMGB1 release from cells, its interaction with receptors, and downstream signaling.
Appendix
Available only for authorised users
Literature
1.
Harris HE, Raucci A: Alarmin (g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep. 2006, 7: 774-778.PubMedCentralPubMed
2.
Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007, 81: 1-5. 10.1189/jlb.0306164.CrossRefPubMed
3.
Bustin M: Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol. 1999, 19: 5237-5246.PubMedCentralCrossRefPubMed
4.
Thomas JO: HMG1 and 2: architectural DNA-binding proteins. Biochem Soc Trans. 2001, 29: 395-401. 10.1042/BST0290395.CrossRefPubMed
5.
Rauvala H, Merenmies J, Pihlaskari R, Korkolainen M, Huhtala ML, Panula P: The adhesive and neurite-promoting molecule p30: analysis of the amino-terminal sequence and production of antipeptide antibodies that detect p30 at the surface of neuroblastoma cells and of brain neurons. J Cell Biol. 1988, 107: 2293-2305. 10.1083/jcb.107.6.2293.CrossRefPubMed
6.
Parkkinen J, Raulo E, Merenmies J, Nolo R, Kajander EO, Baumann M, Rauvala H: Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem. 1993, 268: 19726-19738.PubMed
7.
8.
Urbonaviciute V, Fürnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, Voll RE: Factors masking HMGB1 in human serum and plasma. J Leukoc Biol. 2007, 81: 67-74. 10.1189/jlb.0306196.CrossRefPubMed
9.
Wähämaa H, Vallerskog T, Qin S, Lunderius C, LaRosa G, Andersson U, Harris HE: HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay. J Leukoc Biol. 2007, 81: 129-136. 10.1189/jlb.0506349.CrossRefPubMed
10.
Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ: HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999, 285: 248-251. 10.1126/science.285.5425.248.CrossRefPubMed
11.
Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002, 418: 191-195. 10.1038/nature00858.CrossRefPubMed
12.
Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Müller S, Iannacone M, Traversari C, Bianchi ME, Manfredi AA: HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 2004, 5: 825-830. 10.1038/sj.embor.7400205.PubMedCentralCrossRefPubMed
13.
Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000, 192: 565-570. 10.1084/jem.192.4.565.PubMedCentralCrossRefPubMed
14.
Rouhiainen A, Imai S, Rauvala H, Parkkinen J: Occurrence of amphoterin (HMGB1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost. 2000, 84: 1087-1094.PubMed
15.
Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003, 101: 2652-2660. 10.1182/blood-2002-05-1300.CrossRefPubMed
16.
Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, Andersson U, Yang H, Tracey KJ, Andersson J, Palmblad JE: High mobility group 1 B-box mediates activation of human endothelium. J Intern Med. 2003, 254: 375-385. 10.1046/j.1365-2796.2003.01204.x.CrossRefPubMed
17.
Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, Tracey KJ, Chiorazzi N: High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol. 2004, 173: 307-313.CrossRefPubMed
18.
Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, Cossu G, Bianchi ME: Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol. 2004, 164: 441-449. 10.1083/jcb.200304135.PubMedCentralCrossRefPubMed
19.
Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, Arnold B, Bianchi ME, Manfredi AA, Rovere-Querini P: Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol. 2005, 174: 7506-7515.CrossRefPubMed
20.
Schlueter C, Weber H, Meyer B, Rogalla P, Röser K, Hauke S, Bullerdiek J: Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol. 2005, 166: 1259-1263.PubMedCentralCrossRefPubMed
21.
Semino C, Angelini G, Poggi A, Rubartelli A: NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood. 2005, 106: 609-616. 10.1182/blood-2004-10-3906.CrossRefPubMed
22.
Porto A, Palumbo R, Pieroni M, Aprigliano G, Chiesa R, Sanvito F, Maseri A, Bianchi ME: Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J. 2006, 20: 2565-2566. 10.1096/fj.06-5867fje.CrossRefPubMed
23.
Raman KG, Sappington PL, Yang R, Levy RM, Prince JM, Liu S, Watkins SK, Schmidt AM, Billiar TR, Fink MP: The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol. 2006, 291: G556-565. 10.1152/ajpgi.00055.2006.CrossRefPubMed
24.
Germani A, Limana F, Capogrossi MC: Pivotal advances: high-mobility group box 1 protein – a cytokine with a role in cardiac repair. J Leukoc Biol. 2007, 81: 41-45. 10.1189/jlb.0306165.CrossRefPubMed
25.
Meri S: Loss of self-control in the complement system and innate autoreactivity. Ann N Y Acad Sci. 2007, 1109: 93-105. 10.1196/annals.1398.011.CrossRefPubMed
26.
Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, Ballantyne CM, Gahmberg CG, Bianchi ME, Nawroth PP, Chavakis T: A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 2007, 26: 1129-1139. 10.1038/sj.emboj.7601552.PubMedCentralCrossRefPubMed
27.
Pedrazzi M, Patrone M, Passalacqua M, Ranzato E, Colamassaro D, Sparatore B, Pontremoli S, Melloni E: Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling. J Immunol. 2007, 179: 8525-8532.CrossRefPubMed
28.
Manfredi AA, Capobianco A, Esposito A, De Cobelli F, Canu T, Monno A, Raucci A, Sanvito F, Doglioni C, Nawroth PP, Bierhaus A, Bianchi ME, Rovere-Querini P, Del Maschio A: Maturing den-dritic cells depend on RAGE for in vivo homing to lymph nodes. J Immunol. 2008, 180: 2270-2275.CrossRefPubMed
29.
Bianchi ME, Manfredi AA: High mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev. 2007, 220: 35-46. 10.1111/j.1600-065X.2007.00574.x.CrossRefPubMed
30.
Yang J, Shah R, Robling AG, Templeton E, Yang H, Tracey KJ, Bidwell JP: HMGB1 is a bone-active cytokine. J Cell Physiol. 2008, 214: 730-739. 10.1002/jcp.21268.CrossRefPubMed
31.
Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE: RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol. 2005, 61: 1-9. 10.1111/j.0300-9475.2005.01534.x.CrossRefPubMed
32.
Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, Ishizaka A, Abraham E: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol. 2006, 290: C917-924. 10.1152/ajpcell.00401.2005.CrossRefPubMed
33.
Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E: Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004, 279: 7370-7377. 10.1074/jbc.M306793200.CrossRefPubMed
34.
Dintilhac A, Bernues J: HMGB1 interacts with many apparently unrelated proteins by recognizing short amino acid sequences. J Biol Chem. 2002, 277: 7021-7028. 10.1074/jbc.M108417200.CrossRefPubMed
35.
Li J, Wang H, Mason JM, Levine J, Yu M, Ulloa L, Czura CJ, Tracey KJ, Yang H: Recombinant HMGB1 with cytokine-stimulating activity. J Immunol Methods. 2004, 289: 211-223. 10.1016/j.jim.2004.04.019.CrossRefPubMed
36.
Rouhiainen A, Tumova S, Valmu L, Kalkkinen N, Rauvala H: Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol. 2007, 81: 49-58. 10.1189/jlb.0306200.CrossRefPubMed
37.
Zimmermann K, Völkel D, Pable S, Lindner T, Kramberger F, Bahrami S, Scheiflinger F: Native versus recombinant high-mobility group B1 proteins: functional activity in vitro. Inflammation. 2004, 28: 221-229. 10.1023/B:IFLA.0000049047.61014.e3.CrossRefPubMed
38.
Youn JH, Oh YJ, Kim ES, Choi JE, Shin JS: High mobility group box 1 protein binding to lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol. 2008, 180: 5067-5074.CrossRefPubMed
39.
Sha Y, Zmijewski J, Xu Z, Abraham E: HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol. 2008, 180: 2531-2537.CrossRefPubMed
40.
Ulloa L, Tracey KJ: The 'cytokine profile': a code for sepsis. Trends Mol Med. 2005, 11: 56-63. 10.1016/j.molmed.2004.12.007.CrossRefPubMed
41.
Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi ME: Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003, 22: 5551-5560. 10.1093/emboj/cdg516.PubMedCentralCrossRefPubMed
42.
Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, Rubartelli A: The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 2002, 3: 995-1001. 10.1093/embo-reports/kvf198.PubMedCentralCrossRefPubMed
43.
Ito I, Fukazawa J, Yoshida M: Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem. 2007, 282: 16336-16344. 10.1074/jbc.M608467200.CrossRefPubMed
44.
Youn JH, Shin JS: Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol. 2006, 177: 7889-7897.CrossRefPubMed
45.
Jiang W, Li J, Gallowitsch-Puerta M, Tracey KJ, Pisetsky DS: The effects of CpG DNA on HMGB1 release by murine macrophage cell lines. J Leukoc Biol. 2005, 78: 930-936. 10.1189/jlb.0405208.CrossRefPubMed
46.
Jiang W, Pisetsky DS: The role of IFN-alpha and nitric oxide in the release of HMGB1 by RAW 264.7 cells stimulated with polyinosinic-polycytidylic acid or lipopolysaccharide. J Immunol. 2006, 177: 3337-3343.CrossRefPubMed
47.
Bell CW, Jiang W, Reich CF, Pisetsky DS: The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol. 2006, 291: C1318-1325. 10.1152/ajpcell.00616.2005.CrossRefPubMed
48.
Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, Bucciarelli LG, Moser B, Moxley G, Itescu S, Grant PJ, Gregersen PK, Stern DM, Schmidt AM: RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 2002, 3: 123-135. 10.1038/sj.gene.6363861.CrossRefPubMed
49.
Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Li J, Wang H, Ulloa L, Yang H, Yan XJ, Furie R, Chiorazzi N, Tracey KJ, Andersson U, Harris HE: High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 2002, 46: 2598-2603. 10.1002/art.10540.CrossRefPubMed
50.
Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, Tracey KJ, Andersson U, Harris HE: Successful treatment of collagen-induced arthritis in mice and rats by targeting extra-cellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 2003, 48: 2052-2058. 10.1002/art.11161.CrossRefPubMed
51.
Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T, Komiya S, Maruyama I: High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003, 48: 971-981. 10.1002/art.10859.CrossRefPubMed
52.
af Klint E, Grundtman C, Engström M, Catrina AI, Makrygiannakis D, Klareskog L, Andersson U, Ulfgren AK: Intraarticular gluco-corticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis Rheum. 2005, 52: 3880-3889. 10.1002/art.21488.CrossRefPubMed
53.
Ostberg T, Wähämaa H, Palmblad K, Ito N, Stridh P, Shoshan M, Lotze MT, Harris HE, Andersson U: Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Res Ther. 2008, 10: R1-10.1186/ar2347.PubMedCentralCrossRefPubMed
54.
Palmblad K, Sundberg E, Diez M, Söderling R, Aveberger AC, Andersson U, Harris HE: Morphological characterization of Arthritis Research & Therapy Vol 10 No 3 Pisetsky et al. intra-articular HMGB1 expression during the course of collagen-induced arthritis. Arthritis Res Ther. 2007, 9: R35-10.1186/ar2155.PubMedCentralCrossRefPubMed
55.
Pullerits R, Jonsson IM, Verdrengh M, Bokarewa M, Andersson U, Erlandsson-Harris H, Tarkowski A: High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum. 2003, 48: 1693-1700. 10.1002/art.11028.CrossRefPubMed
56.
Popovic K, Ek M, Espinosa A, Padyukov L, Harris HE, Wahren-Herlenius M, Nyberg F: Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum. 2005, 52: 3639-3645. 10.1002/art.21398.CrossRefPubMed
57.
Barkauskaite V, Ek M, Popovic K, Harris HE, Wahren-Herlenius M, Nyberg F: Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus. 2007, 16: 794-802. 10.1177/0961203307081895.CrossRefPubMed
58.
Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007, 8: 487-496. 10.1038/ni1457.CrossRefPubMed
59.
Jiang W, Pisetsky DS: Expression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus. Ann Rheum Dis. 2008, 67: 727-728. 10.1136/ard.2007.074484.CrossRefPubMed
60.
Voll RE, Urbonaviciute V, Herrmann M, Kalden JR: High mobility group box 1 in the pathogenesis of inflammatory and autoimmune diseases. Isr Med Assoc J. 2008, 10: 26-28.PubMed
61.
Ulfgren AK, Grundtman C, Borg K, Alexanderson H, Andersson U, Harris HE, Lundberg IE: Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum. 2004, 50: 1586-1594. 10.1002/art.20220.CrossRefPubMed
62.
De Mori R, Straino S, Di Carlo A, Mangoni A, Pompilio G, Palumbo R, Bianchi ME, Capogrossi MC, Germani A: Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration. Arterioscler Thromb Vasc Biol. 2007, 27: 2377-2383. 10.1161/ATVBAHA.107.153429.CrossRefPubMed
63.
Tzeng HP, Fan J, Vallejo JG, Dong JW, Chen X, Houser SR, Mann DL: Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes. Am J Physiol Heart Circ Physiol. 2008, 294: H1490-1496. 10.1152/ajpheart.00910.2007.CrossRefPubMed
64.
Ek M, Popovic K, Harris HE, Naucler CS, Wahren-Herlenius M: Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 2006, 54: 2289-2294. 10.1002/art.21969.CrossRefPubMed
65.
Liu K, Mori S, Takahashi HK, Tomono Y, Wake H, Kanke T, Sato Y, Hiraga N, Adachi N, Yoshino T, Nishibori M: Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J. 2007, 21: 3904-3916. 10.1096/fj.07-8770com.CrossRefPubMed
66.
Kim JB, Sig Choi J, Yu YM, Nam K, Piao CS, Kim SW, Lee MH, Han PL, Park JS, Lee JK: HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci. 2006, 26: 6413-6421. 10.1523/JNEUROSCI.3815-05.2006.CrossRefPubMed
67.
Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Wang H, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA. 2004, 101: 296-301. 10.1073/pnas.2434651100.PubMedCentralCrossRefPubMed
68.
Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP: Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2005, 83: 876-886. 10.1007/s00109-005-0688-7.CrossRefPubMed
69.
Lutterloh EC, Opal SM, Pittman DD, Keith JC, Tan XY, Clancy BM, Palmer H, Milarski K, Sun Y, Palardy JE, Parejo NA, Kessimian N: Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care. 2007, 11: R122-10.1186/cc6184.PubMedCentralCrossRefPubMed
70.
Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, Yamamoto Y, Yamamoto H, Iino S, Taniguchi N, Maruyama I: The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005, 115: 1267-1274.PubMedCentralCrossRefPubMed
71.
Wouwer Van de M, Plaisance S, De Vriese A, Waelkens E, Collen D, Persson J, Daha MR, Conway EM: The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost. 2006, 4: 1813-1824. 10.1111/j.1538-7836.2006.02033.x.CrossRefPubMed
72.
Zetterström CK, Jiang W, Wähämaa H, Ostberg T, Aveberger AC, Schierbeck H, Lotze MT, Andersson U, Pisetsky DS, Erlandsson Harris H: Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. J Leukoc Biol. 2008, 83: 31-38. 10.1189/jlb.0507323.CrossRefPubMed
73.
74.
Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, Gallowitsch-Puerta M, Patel NB, Huston BJ, Chavan S, Rosas-Ballina M, Gregersen PK, Czura CJ, Sloan RP, Sama AE, Tracey KJ: Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med. 2007, 13: 210-215. 10.2119/2006-00108.Goldstein.PubMedCentralCrossRefPubMed
75.
de Jonge WJ, Ulloa L: The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol. 2007, 151: 915-929. 10.1038/sj.bjp.0707264.PubMedCentralCrossRefPubMed
76.
Sundberg E, Grundtman C, Af Klint E, Lindberg J, Ernestam S, Ulfgren AK, Harris HE, Andersson U: Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients – a prospective clinical study. Arthritis Res Ther. 2008, 10: R33-10.1186/ar2387.PubMedCentralCrossRefPubMed
Metadata
Title
High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease
Authors
David S Pisetsky
Helena Erlandsson-Harris
Ulf Andersson
Publication date
01-06-2008
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2008
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2440

Other articles of this Issue 3/2008

Arthritis Research & Therapy 3/2008 Go to the issue

Research article

Sleep structure and sleepiness in chronic fatigue syndrome with or without coexisting fibromyalgia

Research article

The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study

Letter

Carotid intima-media thickness and endothelial function: useful surrogate markers for establishing cardiovascular risk in patients with inflammatory rheumatic disease

Research article

Identification of novel monosodium urate crystal regulated mRNAs by transcript profiling of dissected murine air pouch membranes

Research article

Leukocyte numbers and function in subjects eating n-3 enriched foods: selective depression of natural killer cell levels

Review

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits